Toray Advanced Composites and Joby Aviation Finalize a Long-Term Supply Agreement
8.12.2020 17:00:00 EET | Business Wire | Press release
Toray Advanced Composites announces that it has completed a long-term supply agreement with Joby Aviation for the composite material used for its aircraft. The California-based aircraft company will use Toray’s carbon fiber composite materials to bring fast, affordable, and zero-emissions aerial ridesharing to global communities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201208005035/en/
Shown here: In a Joby Aviation composites lab an automated fiber placement (AFP) machine applies composite material used to fabricate aircraft parts. High performance composite materials are essential in making the Joby aircraft lightweight. Location: Joby's Marina, CA facility is the future of manufacturing for Joby. Photographer: John Kaemmerling
Electric aircraft require proven materials that have high-strength and are very lightweight. Carbon fiber composite materials provide the strength-to-weight ratio needed for electric aerospace applications in order to maximize the range and speed of the aircraft. Every aspect of Joby’s aircraft is being optimized for maximum utilization for urban transport and high-quality carbon fiber materials are a key component of achieving their goals. Joby selected Toray Advanced Composite materials due to their proven heritage of meeting mechanical and safety requirements in aerospace and high-performance automotive applications.
JoeBen Bevirt, Founder and CEO, Joby Aviation, said: "Toray’s prepreg carbon fiber systems provide unparalleled specific strength and toughness, which have enabled Joby to develop aircraft with unprecedented capabilities. We are incredibly proud to be working with Toray as we certify this aircraft, and look forward to building a long-lasting partnership."
Joby will operate an affordable, quiet, and clean transportation service, using the revolutionary all-electric, vertical take-off and landing aircraft it has spent the last decade developing. With a range of up to 150 miles and a top speed of 200 mph, the vehicle and the service has the potential to make a significant difference to the lives of travelers. Carbon fiber materials are used throughout the vehicle structure, propulsion systems, and interior components.
“We are very pleased to have finalized this important supply agreement with Joby Aviation, a pioneer in the development of the eVTOL,” says Mr. Toshiyuki Kondo, CEO, Toray Advanced Composites. “As children, we dreamed of being able to fly to a destination in a fraction of the time it would take to drive. That is no longer a fantasy. The electric air taxi is becoming a reality and we at Toray are perfectly positioned to meet the industry’s needs today and in the future. It’s a very exciting time.”
Joby Aviation has spent more than a decade developing its aircraft and plans to bring it into commercial operation as early as 2023. By combining years of development with a world-class team and now a leading carbon fiber composite supplier, Joby is well-positioned to deliver on the promise of aerial ridesharing.
About Joby Aviation
Joby Aviation is a California-based aerospace company that is developing and commercializing all-electric vertical take-off and landing aircraft (designated by the FAA as the S4) to enable the deployment of fast, quiet, and affordable air taxi services. The company’s mission is to deliver people to their destination five times faster than driving would, reduce urban congestion, and accelerate the shift to sustainable modes of transit. Founded in 2009, Joby pioneered the development of eVTOL aircraft and has offices in Santa Cruz, San Carlos, and Marina, California. Find more information at http://www.jobyaviation.com.
About Toray Advanced Composites
Toray Advanced Composites is a leader in the development and production of advanced thermoplastic and thermoset composite materials. The broad product portfolio is incorporated in high performance products for aerospace, space, communications, automotive, consumer, and industrial applications. Toray Advanced Composites has a long heritage of combining state-of-the-art materials technology with world-class technical expertise to deliver a unique customer-centric business model. Production and operation facilities are in North America, Europe, and Asia. Toray Advanced Composites is a subsidiary of the Toray Group. For more information visit, www.toraytac.com
©2020 Toray Advanced Composites. All trademarks are the property of Toray Industries Inc. unless otherwise stated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201208005035/en/
Contact information
Joby Aviation
Press contact:
Mojgan Khalili, press@joby.aero, 408-489-4015
Toray Advanced Composites
Media Inquiries (North America):
Johanna Beckmen, Director of Marketing USA
t +1 669-888-5416
e j.beckmen@toraytac-usa.com
Media Inquiries (Europe, Middle East):
Jenny Hodgson, Marketing Manager EMEA
t +44 1773 536966
e j.hodgson@toraytac-europe.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
